# Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 11-17 Year-Old Subjects

> **NCT00464815** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1025 (actual)

## Conditions studied

- Infections, Meningococcal

## Interventions

- **BIOLOGICAL:** Meningococcal vaccine GSK134612
- **BIOLOGICAL:** Mencevax™ ACWY

## Key facts

- **NCT ID:** NCT00464815
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05-02
- **Primary completion:** 2008-04-16
- **Final completion:** 2008-09-10
- **Target enrollment:** 1025 (ACTUAL)
- **Last updated:** 2018-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00464815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00464815, "Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 11-17 Year-Old Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00464815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*